Adults suffering from moderate to severe chronic hand eczema now have a new treatment option as the European Medicines Agency has authorized Anzupgo. This approval marks a significant advancement for patients who have not found relief with traditional corticosteroid creams.
Effective Treatment Option for Limited Alternatives
Anzupgo, containing the active substance delgocitinib, has demonstrated superior efficacy compared to placebo in clinical trials involving 960 adults. Approximately 20-29% of patients achieved clear or almost clear skin after 16 weeks of treatment, doubling the success rate seen with placebo. The cream is applied twice daily to affected areas and should be continued until symptoms subside.
Safety and Monitoring Measures in Place
The most common side effects reported include mild application site reactions such as itching, redness, and a burning sensation, occurring in about 1% of users. Despite these side effects, the EMA concluded that the benefits of Anzupgo outweigh the risks for patients with limited treatment options.
• Anzupgo offers an alternative for patients unresponsive to corticosteroids.
• The treatment regimen requires consistent application for optimal results.
• Side effects are generally mild and manageable under medical supervision.
• Continuous monitoring ensures the safety and effectiveness of the medication.
Anzupgo’s authorization fills a critical gap in the treatment landscape for chronic hand eczema, providing hope to those who previously had limited therapeutic choices. Healthcare professionals are encouraged to consider this option for eligible patients, ensuring adherence to prescribed usage guidelines for maximum benefit.
The approval process included rigorous evaluation of clinical data, confirming Anzupgo’s effectiveness and safety profile. As the medication becomes available across the EU, patients and physicians will gain access to a tool that can significantly improve quality of life by reducing the persistent discomfort associated with chronic hand eczema.
Ongoing pharmacovigilance will continue to monitor Anzupgo’s performance in the real world, ensuring that any emerging safety concerns are promptly addressed. This proactive approach underscores the EMA’s commitment to patient safety and therapeutic efficacy.
With Anzupgo now available, individuals battling chronic hand eczema have a new, scientifically-backed option to manage their condition effectively. Patients are advised to consult with their healthcare providers to determine the best treatment plan tailored to their specific needs.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
